Fox Chase Cancer Center of Philadelphia and VisEn Medical Inc. of Woburn, Mass., have partnered to advance the Phase I clinical trials of the company’s “smart” fluorescence-activatable imaging agents, which they hope will enable physicians to identify and characterize early-stage disease in oncology patients. The trials initially will focus on ovarian cancer and are scheduled to begin in 2009.